Revolutionizing recombinant adeno-associated virus (rAAV) characterization, Viralgen’s poster presents how high-throughput sequencing (HTS) enables detailed insights into rAAV product integrity, identity, and purity. This innovative approach aligns with stringent quality requirements for advanced gene therapies.
Key Highlights:-
In-depth Analysis: Viralgen's HTS methodology evaluates DNA sequence integrity and fidelity, identifying truncations and off-target events with unparalleled precision.
-
Method Performance: Their process demonstrates exceptional sensitivity and accuracy, paving the way for reliable analysis of rAAV preparations.
-
Regulatory Alignment: These methods set a new benchmark for meeting critical quality attributes (CQAs), ensuring compliance with global standards.
By advancing analytical precision, Viralgen is empowering the development of safer, more effective gene therapies.
